迈克生物股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：唐勇 主管会计工作负责人：尹珊 会计机构负责人（会计主管人员）：游平 汇总表 第 1 页 | | | | 占用方与上市公 | 上市公司核算的 | 年期初占 | 2025 年占用累 | 年占用资 | | 年偿还累 | 2025 年上半 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | | | | 2025 | 计发生金额 | 2025 | 2025 | | 年末占用资 | 占用形成原因 | 占用性质 | | | | | 司的关联关系 | 会计科目 | 用资金余额 | （不含利息） | 金的利息(如有) | | 计发生金额 | 金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | 小计 | | - | - | - | - | - | ...

迈克生物股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、监事会会议召开情况 1、迈克生物股份有限公司（以下简称"公司"）第六届监事会第五次会议通知于2025年7月 21日以邮件、短信的方式向全体监事发出并送达。 证券代码：300463 证券简称：迈克生物 公告编号：2025-067 2、本次监事会于2025年7月31日在公司会议室以现场方式召开。 3、本次会议应出席会议的监事3人，实际出席会议的监事3人。 4、本次会议由监事会主席邹媛女士召集和主持。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、法规和《迈克生物股份有限公司章程》（以下简称"《公司章程》"）的有关规 定。 二、监事会会议审议情况 经与会监事认真审议，本次会议以书面表决方式通过以下议案： （一）审议通过《关于公司2025年半年度报告全文及其摘要的议案》 经审核，监事会认为：公司董事会对《2025 年半年度报告》及其摘要的编制和审议程序符 合相关法律、法规及公司章程的规定，且 2025 年半年度报告 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) [Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, the company experienced significant declines in both operating revenue and net profit, with operating revenue decreasing by **15.94%** year-on-year and net profit attributable to shareholders plummeting by **83.12%**, or **68.24%** after deducting non-recurring gains and losses; total assets slightly increased by **0.43%** while net assets attributable to shareholders marginally decreased by **0.73%** [Key Accounting Data and Financial Indicators](index=8&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company faced significant performance pressure during the reporting period, with operating revenue at **1.075 billion CNY**, a **15.94%** year-on-year decrease, and net profit attributable to parent company shareholders at **34.04 million CNY**, a sharp **83.12%** decline; basic earnings per share were **0.0556 CNY/share**, down **83.25%**, and net cash flow from operating activities was **161.79 million CNY**, a **23.93%** decrease Key Accounting Data and Financial Indicators | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 1,075,034,096.39 | 1,278,911,868.07 | -15.94% | | Net Profit Attributable to Shareholders (CNY) | 34,042,488.83 | 201,725,714.09 | -83.12% | | Net Profit Attributable to Shareholders (Excl. Non-Recurring Items) (CNY) | 63,056,198.41 | 198,561,803.72 | -68.24% | | Net Cash Flow from Operating Activities (CNY) | 161,789,633.02 | 212,680,247.22 | -23.93% | | Basic EPS (CNY/share) | 0.0556 | 0.3320 | -83.25% | | Weighted Average ROE | 0.53% | 3.11% | -2.58% | | **Indicator** | **End of Current Period** | **End of Prior Year** | **YoY Change** | | Total Assets (CNY) | 8,010,813,632.54 | 7,976,306,737.10 | 0.43% | | Net Assets Attributable to Shareholders (CNY) | 6,322,440,254.33 | 6,369,056,728.78 | -0.73% | [Non-Recurring Gains and Losses and Amounts](index=8&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) During the reporting period, the company's total non-recurring gains and losses amounted to **-29.01 million CNY**, primarily influenced by a **10.92 million CNY** loss from fair value changes in other non-current financial assets and **27.23 million CNY** in other non-operating expenses due to tax surcharges and equipment write-offs Non-Recurring Gains and Losses (CNY) | Item | Amount (CNY) | Description | | :--- | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | 1,995,701.15 | - | | Government Grants Recognized in Current P&L | 7,195,511.01 | - | | Gains/Losses from Fair Value Changes of Financial Assets/Liabilities | -10,920,599.85 | Primarily fair value change losses on other non-current financial assets during the reporting period | | Other Non-Operating Income and Expenses | -27,228,990.61 | Primarily tax surcharges paid and equipment write-offs due to updates during the reporting period | | **Total** | **-29,013,709.58** | - | [Management Discussion and Analysis](index=10&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) [Company's Main Business, Operating Model, and Performance Drivers](index=10&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company specializes in R&D, production, sales, and service of in vitro diagnostic (IVD) products, forming a complete industry chain covering biochemical, immunoassay, and molecular diagnostics platforms; despite challenges, autonomous product revenue share increased to **81.11%** and multiple products won centralized procurement bids, laying a foundation for future growth - The company is a leading IVD enterprise in China with one of the most comprehensive product lines, covering biochemical, immunoassay, hematology, and molecular diagnostics platforms, and offering laboratory automation solutions[42](index=42&type=chunk)[50](index=50&type=chunk) - Performance decline is primarily attributed to: 1) revenue structure changes due to **divestment of agency business**; 2) intensified market competition from industry policies (e.g., centralized procurement, mutual recognition of test results) leading to both volume and price reductions; 3) a **22 million CNY** year-on-year increase in credit impairment losses; and 4) a **20 million CNY** reduction in current net profit due to **back taxes and late fees** for 2021-2023[51](index=51&type=chunk) Business Segment Performance (2025 H1) | Business Segment | 2025 H1 Revenue / Share | YoY Change | Key Driving Factors | | :--- | :--- | :--- | :--- | | **Autonomous Products** | 872 million CNY / 81.11% | Revenue -6.49%, Sales +3.79% | Instrument installations (2,409 new units/lines), centralized procurement wins driving sales growth | | **Agency Products** | 193 million CNY / 18.89% | Revenue -42.16% | Company strategically divested agency business to focus on autonomous products | | **Overseas Market** | 108 million CNY | Revenue +37.59% | Active expansion in international markets, 220 new overseas registrations | - The company's chemiluminescence (infectious diseases, sex hormones, tumor markers, etc.) and biochemical (renal function, myocardial enzymes, glucose metabolism, etc.) products were selected into Group A in provincial alliance centralized procurement in Anhui, Jiangxi, and other regions, with centralized procurement wins driving significant sales growth for related products, such as a **21.17%** year-on-year increase in tumor marker sales[54](index=54&type=chunk) [Core Competitiveness Analysis](index=18&type=section&id=%E4%BA%8C%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competitiveness lies in its comprehensive "8+1" product platform and smart laboratory solutions, sustained high R&D investment (accounting for **22.38%** of autonomous product revenue) with over **60%** core raw material self-sufficiency, an international-standard full lifecycle quality management and metrological traceability system, and a global marketing network covering **106** countries and regions providing full-cycle laboratory ecosystem empowerment services - **Product Innovation**: Established an "8+1" product platform covering biochemical, immunoassay, and hematology fields, with **519** autonomous product registrations capable of meeting **80%** of medical institutions' project needs, while also launching the Mike "Smart Lab" solution to promote laboratory automation and intelligence upgrades[60](index=60&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk) - **Technological Innovation**: Maintained high R&D investment, with **195 million CNY** invested during the reporting period, accounting for **22.38%** of autonomous product revenue, supported by **1,076** R&D personnel and achieving over **60%** core raw material self-sufficiency, ensuring independent control of key technologies[63](index=63&type=chunk)[64](index=64&type=chunk) - **Quality System**: Established a quality control system covering the entire product lifecycle, with its testing center laboratory accredited by CNAS; the company is the first Chinese enterprise representative in JCTLM, having established nearly **90** reference methods, demonstrating industry-leading metrological traceability capabilities[66](index=66&type=chunk)[67](index=67&type=chunk)[69](index=69&type=chunk) - **Global Marketing Network**: Overseas business covers **106** countries and regions, collaborating with over **400** distributors, with overseas sales revenue increasing by **37.59%** year-on-year during the reporting period; the domestic market covers over **9,400** medical institutions, with a **59%** coverage rate in tertiary hospitals[71](index=71&type=chunk)[72](index=72&type=chunk) [Main Business Analysis](index=21&type=section&id=%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) During the reporting period, the company's main business revenue was **1.075 billion CNY**, a **15.94%** year-on-year decrease, with a gross profit margin of **56.96%**, largely consistent with the prior year; the performance decline was primarily due to a **42.16%** drop in agency product revenue, while autonomous product revenue, despite a **6.49%** year-on-year decrease, maintained a high gross profit margin of **71.24%**; by region, overseas business showed strong growth, with revenue increasing by **37.59%** year-on-year and gross profit margin improving by **7.37** percentage points Main Business Performance by Category and Region | Category | Operating Revenue (CNY) | Operating Cost (CNY) | Gross Profit Margin | Revenue YoY Change | Cost YoY Change | Gross Profit Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Total** | **1,075,034,096.39** | **462,706,408.47** | **56.96%** | **-15.94%** | **-15.86%** | **-0.04%** | | Autonomous Products | 871,985,074.94 | 250,802,155.93 | 71.24% | -6.49% | -2.47% | -1.18% | | Agency Products | 193,072,426.78 | 208,303,051.28 | -7.89% | -42.16% | -27.71% | -21.57% | | Southwest Region | 393,994,543.97 | 189,019,598.08 | 52.02% | -19.67% | -13.68% | -3.33% | | East China Region | 217,017,515.45 | 89,748,037.63 | 58.64% | -13.70% | -20.60% | 3.59% | | Overseas Region | 107,805,168.24 | 56,231,556.18 | 47.84% | 37.59% | 20.57% | 7.37% | [Analysis of Assets and Liabilities](index=22&type=section&id=%E4%BA%94%E3%80%81%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) As of the end of the reporting period, the company's total assets were **8.011 billion CNY**, a slight increase of **0.43%** from the beginning of the period, with changes in asset structure including a **15.53%** decrease in accounts receivable due to enhanced collection management, a **14.85%** increase in inventory due to increased finished instrument stock, and a **12.34%** increase in construction in progress due to higher investment in the IVD industrial park project; on the liability side, short-term and long-term borrowings increased by **30.04%** and **169.81%** respectively to meet project funding needs Asset and Liability Changes | Asset/Liability Item | Period-End Balance (CNY) | Change from Prior Year-End | Main Reasons for Change | | :--- | :--- | :--- | :--- | | Accounts Receivable | 1,320,355,324.96 | -15.53% | Strengthened accounts receivable management, accelerated collection | | Inventory | 1,035,486,438.13 | +14.85% | Increased finished instrument inventory to support smart laboratory promotion | | Construction in Progress | 1,239,206,813.41 | +12.34% | Increased investment in Tianfu International Bio-City IVD Industrial Park project | | Short-Term Borrowings | 331,715,986.27 | +30.04% | Increased short-term borrowings based on financing needs | | Long-Term Borrowings | 496,763,065.97 | +169.81% | Increased project loans to meet industrial park project investment | [Investment Analysis](index=24&type=section&id=%E5%85%AD%E3%80%81%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) During the reporting period, the company's total investment was **359 million CNY**, a **22.81%** year-on-year decrease, with significant non-equity investments primarily in the "Mike Bio Tianfu International Bio-City IVD Industrial Park Project," which has a total planned investment of **2.08 billion CNY** and has accumulated **1.229 billion CNY** in investment as of the end of the reporting period, reaching **59.07%** project progress; regarding raised funds, the company modified and extended some of its fundraising projects, terminating the "Instant Diagnostic Product Production Line Sub-project" and reallocating the remaining funds to the "IVD Product Technology R&D Center Sub-project" - The company's most significant investment project is the "Tianfu International Bio-City IVD Industrial Park," with **132 million CNY** invested during the reporting period and a cumulative investment of **1.229 billion CNY**, funded by raised capital, loans, and self-owned funds[87](index=87&type=chunk) - Regarding the use of raised funds, the company terminated the "Instant Diagnostic Product Production Line" sub-project due to insufficient technical and channel competitiveness, reallocating the remaining **86.91 million CNY** to the "IVD Product Technology R&D Center" sub-project[93](index=93&type=chunk)[99](index=99&type=chunk) - Due to external environmental impacts and extended equipment procurement and debugging cycles, the company repeatedly extended the completion dates for the "Tianfu International Bio-City IVD Industrial Park Project" and the "Informationization and Marketing Network Construction Project"[96](index=96&type=chunk)[97](index=97&type=chunk) [Risks and Countermeasures](index=31&type=section&id=%E5%8D%81%E3%80%81%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company faces key risks including policy changes, intensified market competition, technological innovation and leakage, talent loss, and raw material supply risks; specifically, medical reform policies like centralized procurement and DRGs/DIP payment may compress profit margins, industry competition has escalated from product upgrades to business model competition, protecting core technologies and retaining key talent are ongoing challenges for sustainable development, and reliance on imported core raw materials poses supply shortage risks; the company actively responds by closely monitoring policies, enhancing comprehensive competitiveness, improving confidentiality and incentive mechanisms, and increasing raw material self-research - **Policy Change Risk**: Policies such as centralized procurement, separation of technical services and consumables, and DRGs/DIP payments will compress corporate profit margins and accelerate industry consolidation; the company responds by closely monitoring policies and flexibly adjusting its operating strategies[108](index=108&type=chunk) - **Intensified Market Competition Risk**: Industry competition has escalated from single-product pricing to comprehensive competition in capital, product organization, and integrated service capabilities; the company enhances its competitiveness by improving product, channel, and R&D capabilities[109](index=109&type=chunk) - **Technological Innovation and Leakage Risk**: R&D innovation carries uncertainties, and most core technologies exist in non-patent forms, posing leakage risks; the company addresses this by increasing R&D investment and improving confidentiality mechanisms[111](index=111&type=chunk) - **Raw Material Supply Risk**: The domestic IVD industry's core raw materials still primarily rely on imports, facing supply shortage risks from trade frictions; the company mitigates this risk by increasing investment in raw material self-research to enhance self-sufficiency[113](index=113&type=chunk) [Corporate Governance, Environment, and Society](index=34&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) [Changes in Directors, Supervisors, and Senior Management](index=34&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, due to the company's board of directors and supervisory board re-election, some directors, supervisors, and senior management members changed, with Yang Hui, Fu Daiguo, Wang Lin, and Deng Hong leaving their original positions upon term expiration, while Deng Hong was elected as a new director, Xia Changyuan, Liu Yi, and Chen Xiaoli were elected as new independent directors or supervisors, and Lin Xin was appointed as a senior director - On January 13, 2025, due to re-election, several directors, supervisors, and senior management personnel of the company changed, including the departure of some individuals and the election and appointment of new members[120](index=120&type=chunk) [Implementation of Equity Incentive Plans](index=34&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E8%AE%A1%E5%88%92%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E6%88%96%E5%85%B6%E4%BB%96%E5%91%98%E5%B7%A5%E6%BF%80%E5%8A%B1%E6%8E%AA%E6%96%BD%E7%9A%84%E5%AE%9E%E6%96%BD%E6%83%85%E5%86%B5) The company launched a restricted stock incentive plan in 2024, but in June 2025, after deliberation by the board of directors, supervisory board, and general meeting of shareholders, it was decided to terminate the plan, consequently repurchasing and canceling the already granted first-class restricted shares and invalidating the granted second-class restricted shares - In June 2024, the company granted **7.3029 million** restricted shares to **117** incentive recipients[124](index=124&type=chunk)[125](index=125&type=chunk) - In June 2025, the company decided to terminate the 2024 restricted stock incentive plan and repurchase, cancel, and invalidate all granted restricted shares[126](index=126&type=chunk) [Social Responsibility (ESG)](index=35&type=section&id=%E4%BA%94%E3%80%81%E7%A4%BE%E4%BC%9A%E8%B4%A3%E4%BB%BB%E6%83%85%E5%86%B5) In environmental protection, the company organized the "Old Material Flow" World Earth Day event and four consecutive years of "Clean Mountain Action" parent-child environmental public welfare activities to enhance employee environmental awareness and practice green concepts; in community service, the company established the "Maidou Study Club" public welfare project, offering IVD and biomedical knowledge popularization to young people, with **202** students from multiple schools participating - **Environmental Protection**: Promoted a zero-waste lifestyle and organized employees and their families to participate in environmental practices through activities like "Old Material Flow" and "Clean Mountain Action"[127](index=127&type=chunk)[128](index=128&type=chunk) - **Community Service and Science Popularization**: Established the "Maidou Study Club" public welfare project, providing free IVD industry science education and practical platforms for young people, attracting **202** students from **5** schools[130](index=130&type=chunk) [Significant Matters](index=37&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Significant Guarantees](index=40&type=section&id=%E4%BA%8C%E3%80%81%E9%87%8D%E5%A4%A7%E6%8B%85%E4%BF%9D) As of the end of the reporting period, the company's actual total guarantees amounted to **605 million CNY**, representing **9.57%** of the company's net assets, including **342 million CNY** in external guarantees provided to distributors and **263 million CNY** in guarantees provided to its subsidiary, Mike Medical Actual Guarantee Balances (CNY) | Guarantee Type | Actual Guarantee Balance at Period-End (CNY) | | :--- | :--- | | External Guarantees (for Distributors) | 342,000,000.00 | | Guarantees for Subsidiaries (Mike Medical) | 263,070,100.00 | | **Total** | **605,070,100.00** | - The company's actual total guarantee amount accounts for **9.57%** of its net assets[150](index=150&type=chunk) [Significant Matters of Subsidiaries](index=42&type=section&id=%E5%8D%81%E5%9B%9B%E3%80%81%E5%85%AC%E5%8F%B8%E5%AD%90%E5%85%AC%E5%8F%B8%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9) During the reporting period, to advance its globalization strategy, the company established new wholly-owned subsidiaries in Thailand and Hong Kong; concurrently, to focus on core businesses and optimize channels, the company transferred its **52%** equity in controlling subsidiary Shanxi Mike and **51%** equity in Shandong Mike - **New Subsidiaries**: Established sales and service subsidiaries in Thailand and a global marketing network holding platform in Hong Kong to advance the "16+1" globalization strategy[155](index=155&type=chunk) - **Disposal of Subsidiaries**: To optimize resource allocation, the company transferred its controlling stakes in Shanxi Mike and Shandong Mike for **8.28 million CNY** and **17.41 million CNY**, respectively[156](index=156&type=chunk) [Share Changes and Shareholder Information](index=43&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) [Share Changes](index=43&type=section&id=%E4%B8%80%E3%80%81%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company's total share capital remained unchanged at **612,469,590** shares; due to changes in directors, supervisors, and senior management, restricted shares increased by **980,256** shares, with a corresponding decrease in unrestricted shares; additionally, the company completed its share repurchase plan, accumulating **3.958 million** shares at a total cost of approximately **50.02 million CNY**, later deciding to cancel these repurchased shares to reduce registered capital - Due to the re-election of directors, supervisors, and senior management, some executives resigned or were newly appointed, leading to a structural change between restricted and unrestricted shares, while the total share capital remained unchanged[159](index=159&type=chunk)[160](index=160&type=chunk) - The company completed its share repurchase plan, repurchasing a cumulative **3.958 million** shares (**0.65%** of total share capital) for a total of **50.02 million CNY**; originally intended for equity incentives, these shares were later designated for "cancellation to reduce registered capital"[161](index=161&type=chunk) [Shareholder Numbers and Shareholding](index=45&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had **34,958** common shareholders; among the top ten shareholders, the actual controllers Tang Yong, Wang Dengming, and Liu Qilin are parties acting in concert, holding a combined **23.95%** of shares; Guo Lei, holding **5.84%** of shares, is a party acting in concert with two private equity funds under Shanghai Axing Investment; some major shareholders have pledged their shares Top Shareholders and Shareholding | Shareholder Name | Shareholder Type | Shareholding Percentage | Shares Held at Period-End | Pledge Status | | :--- | :--- | :--- | :--- | :--- | | Tang Yong | Domestic Natural Person | 11.11% | 68,062,301 | Pledged 17,700,000 | | Wang Dengming | Domestic Natural Person | 7.43% | 45,534,495 | - | | Guo Lei | Overseas Natural Person | 5.84% | 35,774,906 | Pledged 22,308,000 | | Liu Qilin | Domestic Natural Person | 5.41% | 33,127,360 | - | | Chen Mei | Domestic Natural Person | 4.30% | 26,320,900 | Pledged 14,720,000 | - Tang Yong, Wang Dengming, and Liu Qilin are parties acting in concert (actual controllers) of the company; Guo Lei is a party acting in concert with funds under Shanghai Axing Investment Management Co., Ltd[166](index=166&type=chunk) [Bond-Related Information](index=49&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no bond-related matters during the reporting period - The company had no bond-related matters during this reporting period[173](index=173&type=chunk) [Financial Report](index=50&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) [Financial Statements](index=50&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This semi-annual financial report is unaudited; the consolidated balance sheet shows total assets of **8.011 billion CNY**, total liabilities of **1.639 billion CNY**, and total equity attributable to parent company shareholders of **6.322 billion CNY**; the consolidated income statement reports operating revenue of **1.075 billion CNY**, total operating costs of **1.007 billion CNY**, total profit of **28 million CNY**, net profit of **37 million CNY**, with **34 million CNY** attributable to parent company shareholders; the consolidated cash flow statement indicates net cash inflow from operating activities of **162 million CNY**, net outflow from investing activities of **321 million CNY**, net inflow from financing activities of **169 million CNY**, and cash and cash equivalents balance of **652 million CNY** at period-end Consolidated Balance Sheet Summary (June 30, 2025) | Item | Period-End Balance (CNY) | Period-Beginning Balance (CNY) | | :--- | :--- | :--- | | Total Assets | 8,010,813,632.54 | 7,976,306,737.10 | | Total Liabilities | 1,638,527,023.76 | 1,552,644,190.08 | | Total Equity Attributable to Parent Company Owners | 6,322,440,254.33 | 6,369,056,728.78 | | Total Liabilities and Owners' Equity | 8,010,813,632.54 | 7,976,306,737.10 | Consolidated Income Statement Summary (2025 Half-Year) | Item | 2025 Half-Year (CNY) | 2024 Half-Year (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 1,075,034,096.39 | 1,278,911,868.07 | | Total Operating Costs | 1,006,684,937.26 | 1,078,405,645.65 | | Total Profit | 28,409,089.61 | 223,137,098.52 | | Net Profit | 36,539,905.57 | 202,489,859.89 | | Net Profit Attributable to Parent Company Shareholders | 34,042,488.83 | 201,725,714.09 | Consolidated Cash Flow Statement Summary (2025 Half-Year) | Item | 2025 Half-Year (CNY) | 2024 Half-Year (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 161,789,633.02 | 212,680,247.22 | | Net Cash Flow from Investing Activities | -320,800,087.39 | -291,207,141.87 | | Net Cash Flow from Financing Activities | 169,425,681.25 | 196,011,670.60 | | Net Increase in Cash and Cash Equivalents | 10,938,714.29 | 117,701,765.62 |

迈克生物股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、董事会会议召开情况 1、迈克生物股份有限公司（以下简称"公司"）第六届董事会第五次会议通知于 2025 年 7 月 21 日以邮件、短信的方式向全体董事发出并送达。 2、本次会议于 2025 年 7 月 31 日在公司会议室以现场和通讯相结合的方式召开。 3、本次会议应出席会议的董事 9 人，实际出席会议的董事 9 人。 4、会议由董事长唐勇先生召集并主持，公司监事、部分高级管理人员列席了会议。 5、本次会议的召集、召开及表决程序符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、法规、规范性文件以及《迈克生物股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，会议合法、有效。 证券代码：300463 证券简称：迈克生物 公告编号：2025-066 表决结果：9 票赞成，0 票反对，0 票弃权，0 票回避 （二）审议通过《关于公司 2025 年半年度募集资金存放与使用情况专项报告的议案》 公司严格按照《公司法》《证券法》《深圳证券交易所上 ...

迈克生物7月31日晚间披露2025年半年报，公司上半年实现营业收入10.75亿元，同比下降15.94%；归属 于上市公司股东的净利润3404.25万元，同比下降83.12%；基本每股收益0.0556元。公司计划不派发现 金红利，不送红股，不以公积金转增股本。 ...

迈克生物（300463）公告，2025年上半年营业收入10.75亿元，同比下降15.94%。归属于上市公司股东 的净利润3404.25万元，同比下降83.12%。公司计划不派发现金红利，不送红股，不以公积金转增股 本。 ...

格隆汇7月29日丨迈克生物(300463.SZ)于投资者互动平台表示，公司目前的已获证产品中，暂无基孔肯 雅热病毒的检测产品。 ...

迈克生物股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局颁发的《医 疗器械注册证》（体外诊断试剂），具体情况如下： 一、产品注册证具体情况 证券代码:300463 证券简称:迈克生物 公告编号:2025-062 三、风险提示 上述注册证书涉及的产品实际销售情况取决于未来市场推广效果，目前尚无法预测该产品 对公司未来营业收入的影响，敬请广大投资者注意投资风险。 特此公告。 迈克生物股份有限公司 董事会 二〇二五年七月二十一日 第 1 页 共 1 页 | 产品名称 | | 注册证书 | 注册 | | | 注册证有效期 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 编号 | 类别 | | | | | | | 肺炎支原体 抗 体检测试剂盒（直接 | IgG | | | | | | | 本产品用于体外定性检测人血 清或血浆样本中的肺炎支原体 | | | | ...

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

迈克生物股份有限公司 证券代码:300463 证券简称:迈克生物 公告编号:2025-061 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）于近日收到四川药品监督管理局颁发的《医 疗器械注册证》（体外诊断试剂），具体情况如下： 二、对公司的影响 凝血因子Ⅱ、V、Ⅶ、Ⅹ活性测定试剂盒（凝固法）均系公司凝血平台新试剂产品，主要 用于凝血因子Ⅱ、V、Ⅶ、Ⅹ缺乏或活性减低治疗监测，配套公司全自动凝血分析系统H 2600、 H 3800系列、H 5000系列。新产品取得注册证进一步丰富了公司产品项目菜单，有助于提升公 司市场综合竞争力，对市场的拓展以及公司未来的经营将产生积极影响。 三、风险提示 上述注册证书涉及的产品实际销售情况取决于未来市场推广效果，目前尚无法预测该产品 对公司未来营业收入的影响，敬请广大投资者注意投资风险。 第 1 页 共 2 页 证券代码:300463 证券简称:迈克生物 公告编号:2025-061 特此公告。 迈克生物股份有限公司 董事会 二〇二五年七月十六日 第 2 ...